Table 1. Baseline characteristics of the patients in the randomized intervention groups.
| Baseline Characteristic | Intermittent Anticoagulation (n=29) | Continuous Anticoagulation (n=29) | P-value | ||
|---|---|---|---|---|---|
| Age (years) | 62.5±12.2 | 60.9±14.4 | 0.66 | ||
| Male | 17 | 59% | 16 | 55% | 0.79 |
| Body mass index (kg/m2) | 33.0±8.2 | 32.3±8.4 | 0.77 | ||
| Systolic Blood Pressure (mmHg) | 120.9±12.9 | 125.8±20.9 | 0.29 | ||
| Diastolic Blood Pressure (mmHg) | 72.9±8.3 | 74.3±11.4 | 0.57 | ||
| Heart rate (beats per minute) | 70.1±13.9 | 67.5±11.0 | 0.42 | ||
| Years with atrial fibrillation | 0.74 | ||||
| <1 year | 5 | 17% | 6 | 21% | |
| ≥1 year | 24 | 83% | 23 | 79% | |
| Congestive heart failure | 2 | 7% | 7 | 24% | 0.14 |
| Coronary artery disease | 7 | 25% | 10 | 36% | 0.38 |
| Diabetes | 10 | 34% | 8 | 28% | 0.57 |
| Sleep Apnea | 4 | 14% | 10 | 36% | 0.06 |
| Hypertension | 26 | 90% | 24 | 83% | 0.71 |
| CHADS2 Score | 0.86 | ||||
| 0-1 | 15 | 52% | 13 | 45% | |
| 2 | 11 | 38% | 13 | 45% | |
| ≥3 | 3 | 10% | 3 | 10% | |
| Mean (±SD) | 1.6±0.7 | 1.6±0.9 | 0.87 | ||
| CHA2DS2-VASc Score | 0.59 | ||||
| 0-1 | 7 | 24% | 3 | 10% | |
| 2 | 9 | 31% | 13 | 45% | |
| ≥3 | 13 | 45% | 13 | 45% | |
| Mean (±SD) | 2.5±1.2 | 2.7±1.3 | 0.60 | ||
| HAS-BLED Score | 0.54 | ||||
| 0-2 | 21 | 72% | 23 | 79% | |
| ≥3 | 8 | 28% | 6 | 21% | |
| Mean (±SD) | 1.9±0.9 | 1.6±1.1 | 0.24 | ||
| Smoking Status | 0.59 | ||||
| Current | 3 | 10% | 5 | 17% | |
| Former | 12 | 41% | 9 | 31% | |
| Never | 14 | 48% | 15 | 52% | |
| Employment status | 0.81 | ||||
| Disabled, do not work | 2 | 7% | 3 | 10% | |
| Full-time employed | 15 | 52% | 16 | 55% | |
| Homemaker | 2 | 7% | 3 | 10% | |
| Retired | 10 | 34% | 7 | 24% | |
| Education status | 0.86 | ||||
| < High School | 1 | 3% | 1 | 3% | |
| High School/GED | 6 | 21% | 5 | 17% | |
| Vo-tech/College | 22 | 76% | 23 | 79% | |
| Antithrombotic or anticoagulant medications at randomization* | |||||
| Warfarin | 3 | 10% | 4 | 14% | 1.0 |
| Aspirin | 13 | 45% | 9 | 31% | 0.28 |
| Clopidogrel | 2 | 7% | 0 | 0% | 1.0 |
| Apixaban | 4 | 14% | 5 | 17% | 1.0 |
| Dabigatran | 2 | 7% | 2 | 7% | 1.0 |
| Rivaroxaban | 7 | 24% | 6 | 21% | 0.75 |
| None | 4 | 14% | 7 | 24% | 0.32 |
| Creatinine (mg/dL) | 1.2±0.8 | 1.0±0.3 | 0.19 | ||
| Hemoglobin (g/dL) | 13.3±1.9 | 13.6±1.7 | 0.51 | ||
*
Patients could select multiple agents and therefore, the counts do not sum to the total number of patients.